ArticlePathology oncology research : POR2014
MicroRNA-181a functions as an oncomir in gastric cancer by targeting the tumour suppressor gene ATM.
Article in Pathology oncology research : POR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Environmental factors in gastric carcinogenesis and preventive intervention strategies.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2025Review
- Review
- Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics.Metabolic brain disease · 2023Review
- Pinostrobin, a fingerroot compound, regulates miR-181b-5p and induces acute leukemic cell apoptosis.Scientific reports · 2023Article
- Signaling pathways and therapeutic interventions in gastric cancer.Signal transduction and targeted therapy · 2022Review
- Higher ATM expression in lymphoblastoid cell lines from centenarian compared with younger women.Drug development research · 2022Article
- Autophagy inhibits cancer stemness in triple-negative breast cancer via miR-181a-mediated regulation of ATG5 and/or ATG2B.Molecular oncology · 2022Article
- Expression of miR-181a in Circulating Tumor Cells of Ovarian Cancer and Its Clinical Application.ACS omega · 2021Article
- miR-181a, delivered by hypoxic PTC-secreted exosomes, inhibits DACT2 by downregulating MLL3, leading to YAP-VEGF-mediated angiogenesis.Molecular therapy. Nucleic acids · 2021Article
- Prognostic value of microRNA-125a/b family in patients with gastric cancer: a meta-analysis.Gastroenterology and hepatology from bed to bench · 2021Review
- Article
- Serum microRNA-381: A Potential Marker for Early Diagnosis of Gastric Cancer.Yonsei medical journal · 2019Article
- MicroRNA-181a Functions as an Oncogene in Gastric Cancer by Targeting Caprin-1.Frontiers in pharmacology · 2018Article
- miR-181a-2 downregulates the E3 ubiquitin ligase CUL4A transcript and promotes cell proliferation.Medical oncology (Northwood, London, England) · 2017Article
- MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells.Molecular cancer · 2017Article
- Dysregulation of non-coding RNAs in gastric cancer.World journal of gastroenterology · 2015Review
- miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14.Cancer research · 2015Article
- An integrated analysis of the effects of microRNA and mRNA on esophageal squamous cell carcinoma.Molecular medicine reports · 2015Article
- ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.British journal of cancer · 2015Article
- MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells.Clinical orthopaedics and related research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on our previous experiments, this study is to further investigate the functional significance of miR-181a and its target gene in gastric cancer. Expression of miR-181a was detected by qRT-PCR in three normal gastric tissues and three human gastric cancer cell lines (SGC-7901, MGC-803, and BGC-823 cells). After transfection with miR-181a inhibitor, proliferation, apoptosis, migration, and invasion of the SGC-7901 cells were evaluated. Ataxia-telangiectasia mutation (ATM) was predicted as a target gene of miR-181a with bioinformatics analysis, and was verified by lucifersae reporter assay. Expression of ATM protein in HEK293T cells and tissues was measured by Western Blot. Expression of ATM mRNA in HEK293T cells was measured by RT-PCR. Compared with three non-tumour tissues, the expression of miR-181a in three gastric cancer cells was significantly increased by 26.68, 14.83 and 14.96 folds; Compared with Negative Control(NC) and blank groups, transfection of miR-181a inhibitor led to inhibition of SGC7901 cell proliferation, invasion, and migration as well as promotion of apoptosis. A luciferase reporter assay demonstrated that ATM was a direct target of miR-181a, miR-181a mimics transfection down regulated ATM mRNA and protein expression. There was inverse correlation between miR-181a and ATM protein expression in gastric cancer and normal gastric tissues. Our study demonstrates that over-expression of miR-181a might be involved in development of gastric cancer by promoting proliferation and inhibiting apoptosis probably through directly targeting ATM. miR-181a modulation may be a potential strategy for the development of miRNA-based therapy of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.